首页> 美国卫生研究院文献>Carcinogenesis >Interferon-beta treatment increases human papillomavirus early gene transcription and viral plasmid genome replication by activating interferon regulatory factor (IRF)-1
【2h】

Interferon-beta treatment increases human papillomavirus early gene transcription and viral plasmid genome replication by activating interferon regulatory factor (IRF)-1

机译:干扰素-β治疗可通过激活干扰素调节因子(IRF)-1来提高人乳头瘤病毒的早期基因转录和病毒质粒基因组复制

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Interferons (IFNs) have been used to treat mucosal lesions caused by human papillomavirus (HPV) infection, such as intraepithelial precursor lesions to cancer of the uterine cervix, genital warts or recurrent respiratory papillomatosis, to potentially reduce or eliminate replicating HPV plasmid genomes. Mucosal HPVs have evolved mechanisms that impede IFN-β synthesis and downregulate genes induced by IFN. Here we show that these HPV types directly subvert a cellular transcriptional response to IFN-β as a potential boost in infection. Treatment with low levels of human IFN-β induced initial amplification of HPV-16 and HPV-11 plasmid genomes and increased HPV-16 or HPV-31 DNA copy numbers up to 6-fold in HPV-immortalized keratinocytes. IFN treatment also increased early gene transcription from the major early gene promoters in HPV-16, HPV-31 and HPV-11. Furthermore, mutagenesis of the viral genomes and ectopic interferon regulatory factor (IRF) expression in transfection experiments using IRF-1 , IRF-2 and dual knockout cell lines determined that these responses are due to the activation of IRF-1 interaction with a conserved interferon response element demonstrated in several mucosal HPV early gene promoters. Our results provide a molecular explanation for the varying clinical outcomes of IFN therapy of papillomatoses and define an assay for the modulation of the HPV gene program by IFNs as well as other cytokines and signaling molecules in infection and therapy.
机译:干扰素(IFN)已用于治疗由人乳头瘤病毒(HPV)感染引起的粘膜病变,例如子宫上皮内癌,生殖器疣或复发性呼吸道乳头状瘤的前体病变,以潜在地减少或消除复制的HPV质粒基因组。粘膜HPV已发展出可阻止IFN-β合成并下调由IFN诱导的基因的机制。在这里,我们显示这些HPV类型直接破坏了细胞对IFN-β的转录反应,从而潜在地增强了感染。在HPV永生化的角质形成细胞中,低水平的人IFN-β处理可诱导HPV-16和HPV-11质粒基因组的初始扩增,并使HPV-16或HPV-31 DNA拷贝数增加多达6倍。 IFN治疗还增加了HPV-16,HPV-31和HPV-11中主要早期基因启动子的早期基因转录。此外,在使用IRF-1的转染实验中,病毒基因组的诱变和异位干扰素调节因子(IRF)表达 ,IRF-2 以及双敲除细胞系确定这些应答是由于IRF-1与保守的干扰素应答元件的相互作用而激活的,这些干扰素在几种粘膜HPV早期基因启动子中得到证实。我们的结果为乳头状瘤的IFN治疗的不同临床结果提供了分子解释,并定义了在感染和治疗中通过IFN以及其他细胞因子和信号分子调节HPV基因程序的测定方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号